Real-world data suggest that geriatric assessment fails to stratify risk in treating older adults with lung cancer

ABSTRACT

Introduction: Older adults require attention to risks of treatment toxicity. The purpose of this study was to evaluate epidemiological data and clinical outcomes of patients with lung cancer treated with non-curative intent assessed by geriatric assessment (GA) and restricted access to new therapies.

Methods: We evaluated older adults with non-small cell lung cancer treated with palliative chemotherapy or first generation target therapy who underwent GA. Overall survival (OS) was calculated and we performed univariate and multivariate analysis to determine prognostic factors for OS.

Results: Fifty-four patients aged ≥70 years had a median age of 76 years, 76% was classified as Katz A and 50% as Lawton <27. 68.5% were at risk of malnutrition or malnourished; 61.1% had ≥2 comorbidities. The mean OS was 17.1 months. In the univariate analysis, lower survival results were observed for patients with ECOG≥2 (HR=5.9; p<0.001), higher number of metastasis sites (HR=2.0; p=0.04) and liver metastasis (HR=12.6; p<0.001). In multivariate analysis, male gender, ECOG≥2, more than 2 metastatic sites and liver metastases were associated with higher risk of death. We did not observe differences in survival according to functional capacity.

Conclusion: GA showed no prognostic relationship in our small population. Patients with ECOG≥2, more than 2 metastatic sites and hepatic metastasis presented higher risk of death. For the older population, new treatment modalities are fundamental and outweigh the prognostic importance of the clinical factors of GA.

RESUMO

Introdução: Os adultos mais velhos requerem atenção quanto aos riscos de toxicidade do tratamento. O objetivo deste estudo foi avaliar dados epidemiológicos e desfechos clínicos de pacientes com câncer de pulmão tratados com intenção não curativa submetidos a avaliação geriátrica (AG) e acesso restrito a novas terapias.

Métodos: Avaliamos idosos com câncer de pulmão de células não pequenas tratados com quimioterapia paliativa ou terapia-alvo de primeira geração que realizaram AG. A sobrevida global (SG) foi calculada e realizamos análises univariadas e multivariadas para determinar os fatores prognósticos para SG.

Resultados: Cinquenta e quatro pacientes com idade ≥70 anos tinham uma idade mediana de 76 anos, 76% foram classificados como: Katz A e 50% como Lawton <27. 68,5% estavam em risco de desnutrição ou desnutrição; 61,1% tinham ≥2 comorbidades. O SG médio foi de 17,1 meses. Na análise univariada, piores resultados de sobrevida foram observados para pacientes com ECOG≥2 (HR=5,9; p<0,001), maior número de locais de metástase (HR=2,0; p=0,04) e metástases hepáticas (HR=12,6; p<0,001). Na análise multivariada, sexo masculino, ECOG≥2, mais de 2 locais metastáticos e metástases hepáticas foram associados a maior risco de morte. Não observamos diferenças na sobrevida de acordo com a capacidade funcional.

Conclusão: AG não mostrou relação prognóstica em nossa pequena população. Pacientes com ECOG≥2, mais de 2 locais metastáticos e metástases hepáticas apresentaram maior risco de morte. Para a população idosa, novas modalidades de tratamento são fundamentais e superam a importância prognóstica dos fatores clínicos da AG.

Keywords:

Geriatric assessment - Lung neoplasms - Frail elderly.

Descritores:

Avaliação geriátrica - Neoplasias pulmonares - Idoso frágil.

Publikationsverlauf

Eingereicht: 30. Juni 2021

Angenommen: 24. August 2021

Artikel online veröffentlicht:
24. September 2021

• REFERENCES

• 1 Lichtman SM. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol 2006; Feb; 3: 86-93 https://doi.org/10.1038/ncponc0420
• 2 Castellón TD, Sieving KE. An experimental test of matrix permeability and corridor use by an endemic understory bird. Conserv Biol 2006; 20 (01) 135-145 https://doi.org/10.1111/j.1523-1739.2006.00332.x
• 3 Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol 2004; Apr; 31 (02) 128-136 https://doi.org/10.1053/j.seminoncol.2003.12.024
• 4 Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005; Nov; 11 (06) 449-460 https://doi.org/10.1097/00130404-200511000-00004
• 5 Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005; Nov; 11 (06) 461-473 https://doi.org/10.1097/00130404-200511000-00005
• 6 Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR. et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; Apr; 147 (08) 755-763 https://doi.org/10.1093/oxfordjournals.aje.a009520
• 7 Kim TN, Yang SJ, Yoo HJ, Lim KI, Kang HJ, Song W. et al. Prevalence of sarcopenia and sarcopenic obesity in Korean adults: the Korean sarcopenic obesity study. Int J Obes (Lond) 2009; Jun; 33: 885-892 https://doi.org/10.1038/ijo.2009.130
• 8 Rolland Y, Lauwers-Cances V, Cristini C, Van Kan GA, Janssen I, Morley JE. et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009; Jun; 89 (06) 1895-1900 https://doi.org/10.3945/ajcn.2008.26950
• 9 Yancik R, Ries LA. Cancer in older persons. Magnitude of the problem--how do we apply what we know?. Cancer 1994; 74 (Suppl 7): 1995-2003 https://doi.org/10.1002/1097-0142(19941001)74:7+<1995::aidcncr2820741702>3.0.co;2-y
• 10 Vestal RE. Aging and pharmacology. Cancer 1997; 80 (07) 1302-1310 https://doi.org/10.1002/(sici)1097-0142(19971001)80:7<1302::aidcncr16>3.0.co;2-b
• 11 Kivistö KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995; Dec; 40 (06) 523-530 https://doi.org/10.1111/j.1365-2125.1995.tb05796.x
• 12 Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park) 2008; Aug; 22 (09) 1052-1055
• 13 Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21 (04) 602 https://doi.org/10.1200/JCO.2003.07.071
• 14 Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; May; 94 (09) 65261 https://doi.org/10.1093/jnci/94.9.652
• 15 Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26 (04) 556 https://doi.org/10.1200/JCO.2007.11.5451
• 16 Partridge AH. Non-adherence to endocrine therapy for breast cancer. Ann Oncol 2006; Feb; 17 (02) 183-184 https://doi.org/10.1093/annonc/mdj141
• 17 Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK. et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a populationbased study. Cancer 1998; Jun; 82 (11) 2123-2134
• 18 Howlader NNA, Krapcho M. et al. SEER Cancer Statistics Review. 1975-2010 [Internet]. Bethesda: National Cancer Institute (NIH);; 2013. Available from: http://seer.cancer.gov/csr/1975_2010/
• 19 Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol 2008; Feb; 3 (02) 125-129 https://doi.org/10.1097/JTO.0b013e3181622c17
• 20 Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010; Sep; 21 (09) 1825-1833 https://doi.org/10.1093/annonc/mdq042
• 21 Shah R, Lester JF. Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive nonsmall-cell lung cancer: a clash of the generations. Clin Lung Cancer 2020; May; 21 (03) e216-e28 https://doi.org/10.1016/j.cllc.2019.12.003
• 22 McCusker MG, Russo A, Scilla KA, Mehra KA, Rolfo C. How I treat ALK-positive non-small cell lung cancer. ESMO Open 2019; Jan; 4 (Suppl 2): e000524 https://doi.org/10.1136/esmoopen-2019-000524
• 23 Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol 2017; Nov; 12 (11) 1611-1625 https://doi.org/10.1016/j.jtho.2017.08.002
• 24 Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M. et al. Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol 2017; Jun; 34 (06) 105 https://doi.org/10.1007/s12032-017-0967-5
• 25 Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q. et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. Discov Med 2018; Oct; 26 (143) 155-166
• 26 Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim SW, Costa EC. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med 2019; Nov; 381 (21) 2020-2031 https://doi.org/10.1056/NEJMoa1910231
• 27 Judd J, Borghaei H. Combining immunotherapy and chemotherapy for non-small cell lung cancer. Thorac Surg Clin 2020; May; 30 (02) 199-206 https://doi.org/10.1016/j.thorsurg.2020.01.006
• 28 Zukin M, Barrios CH, Pereira JR, Ribeiro RA, Beato CA, Nascimento YN. et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31 (23) 2849-2853 https://doi.org/10.1200/JCO.2012.48.1911
• 29 The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-smallcell lung cancer. J Natl Cancer Inst 1999; Jan; 91 (01) 66-72 https://doi.org/10.1093/jnci/91.1.66
• 30 Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Shinkai KM. et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006; 24 (22) 3657 https://doi.org/10.1200/JCO.2006.06.1044
• 31 Azzoli CG, Baker Junior S, Temin S, Pao W, Aliff T, Brahmer J. et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251 https://doi.org/10.3779/j.issn.1009-3419.2010.03.15
• 32 Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thacher N. et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15 (03) 419-426 https://doi.org/10.1093/annonc/mdh087
• 33 Corre R, Greillier L, Le Caër H, AudigerValette C, Baize N, Falchero HB. et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol 2016; 34 (13) 1476-1483 https://doi.org/10.1200/JCO.2015.63.5839
• 34 Dettino A, Figueroa MCM, Leite AMM, Chinen LTD, Nicolau UR, Sanches SMS. et al. Geriatric oncology: comprehensive geriatric assessment tools (CGA) implementation and interdisciplinary clinical approach for elderly patients (pts) in AC Camargo Cancer Center (ACCCC), São Paulo, Brazil. J Clin Oncol 2014; 32 (Suppl 15): 9549 https://doi.org/10.1200/jco.2014.32.15_suppl.9549